Media contact: Stéphanie Bardon – communication@genethon.fr – 01.69.47.12.78
February 20, 2009
Gene therapy: Production of the first batch of HIV-derived vectors in Europe for use in a human clinical trial
Genethon, the laboratory created and funded by the AFM (French Association against Myopathies) using donations from Téléthon, today announced that it has produced, controlled and released a batch of lentiviral vectors derived from the human immunodeficiency (HIV) virus for a gene therapy trial in humans in a rare immune deficiency. The… (read more)
February 12, 2008
Neuromuscular diseases: A pharmacological therapeutic approach for certain sarcoglycanopathies
A research team led by Dr Isabelle Richard (CNRS-FRE3087) from the Genethon laboratory financed by the AFM through Téléthon donations has just demonstrated the efficacy of a novel pharmacological strategy in the mouse for certain mutations of alpha-sarcoglycanopathy or LGMD2D, a recessive limb girdle dystrophy. This pharmacological strategy… (read more)
